8-K: Theriva Biologics Gains EMA Nod for VCN-01 Phase 3 Pancreatic Cancer Trial

Theriva Biologics received positive scientific advice from the European Medicines Agency on the design of its pivotal Phase 3 clinical trial for VCN-01 in metastatic pancreatic cancer.

Summary

• Theriva Biologics received Scientific Advice from the European Medicines Agency (EMA) regarding the design of a Phase 3 clinical trial for its lead candidate, VCN-01.
• VCN-01, in combination with gemcitabine/nab-paclitaxel standard-of-care (SoC) chemotherapy, is being developed for the first-line treatment of metastatic pancreatic adenocarcinoma (PDAC).
• The EMA's Committee for Medicinal Products for Human Use (CHMP) agreed that a single, high-quality, double-blinded, randomized, placebo-controlled Phase 3 trial could support a future marketing authorization application (MAA) if it demonstrates a compelling benefit-risk ratio.
• The CHMP concurred with the proposed inclusion/exclusion criteria, primary endpoint (overall survival), secondary endpoints (progression-free survival, duration of response, patient-reported outcomes), sample size, and the use of an adaptive design.
• The EMA recognized the improved overall survival observed in the VIRAGE Phase 2b study, particularly in patients receiving 2 doses of VCN-01, and agreed with a dosing regimen enabling more than 2 doses in the Phase 3 trial, even suggesting more frequent dosing.
• Theriva Biologics plans to schedule an End-of-Phase 2 meeting with the FDA in the first half of 2026 to finalize the design of a pivotal multinational Phase 3 clinical trial.
• The company reported $15.5 million in cash and equivalents as of November 10, 2025, providing a cash runway into Q1 2027.

Sentiment

Score: 8

Explanation: The filing details highly favorable scientific advice from the EMA for a pivotal Phase 3 trial of VCN-01 in metastatic pancreatic cancer, a disease with significant unmet need. The EMA's agreement on key trial design elements, including dosing and adaptive design, and recognition of prior positive Phase 2b data, significantly de-risks the regulatory pathway in Europe. This positive feedback, combined with existing Fast Track and Orphan Drug designations, provides strong validation for the program and a clear path to advance.

Positives

• The EMA's CHMP provided overall agreement on the proposed Phase 3 clinical trial design for VCN-01 in metastatic PDAC.
• CHMP agreed on key trial parameters including sample size, repeated dosing of VCN-01, and an adaptive design to optimize timelines and outcomes.
• The EMA recognized the increased improvement in overall survival observed in the VIRAGE Phase 2b study, especially with 2 doses of VCN-01, and agreed to a dosing regimen allowing more than 2 doses in Phase 3.
• VCN-01 has received Orphan Drug designation for metastatic PDAC in Europe and the USA, and Fast Track designation in the USA.
• VCN-01 also holds Rare Pediatric Disease designation for retinoblastoma, indicating its potential in another challenging childhood cancer.
• The company has a cash runway into Q1 2027, supporting regulatory activities, protocol development, and partnering efforts for its pivotal trials.

Risks

• Ability to finalize the pivotal Phase 3 trial design.
• Ability to reach clinical milestones as anticipated, including patient enrollment.
• Generating positive clinical data that establishes VCN-01's improved clinical outcomes for patients.
• Product candidates demonstrating safety and effectiveness, and results consistent with prior results.
• Ability to complete clinical trials on time and achieve desired results and benefits.
• Ability to obtain regulatory approval for commercialization or comply with ongoing regulatory requirements.
• Regulatory limitations relating to the ability to promote or commercialize product candidates for specific indications.
• Acceptance of product candidates in the marketplace and successful development, marketing, or sale.
• Developments by competitors that render products obsolete or non-competitive.
• Ability to maintain license agreements.
• Continued maintenance and growth of the patent estate.
• Ability to continue to remain well financed.

Future Outlook

The company plans to finalize the design of a pivotal multinational Phase 3 trial for VCN-01 in metastatic PDAC after an End-of-Phase 2 meeting with the FDA in H1 2026. They anticipate that administering 3 or more doses of VCN-01 in the Phase 3 trial, as suggested by EMA, should provide an even greater survival benefit. Regulatory clarity is considered essential for ongoing partnering efforts for VCN-01 programs. Further interactions with EMA and FDA are planned in 2026 to seek advice on a potential Phase 2/3 trial for VCN-01 in retinoblastoma. The current cash runway is expected to support regulatory activities, protocol development, and partnering efforts until Q1 2027.

Management Comments

• "We are very encouraged by the scientific advice we received from the EMA regarding our proposed pivotal Phase 3 trial of VCN-01 plus gemcitabine/nab-paclitaxel SoC in metastatic PDAC patients."
• "We are particularly pleased with EMA agreement on the VCN-01 macrocycle dosing regimen."
• "As we demonstrated in the VIRAGE Phase 2b study, patients who received 2 doses of VCN-01 had improved survival outcomes, therefore we anticipate 3 or more doses of VCN-01 should provide an even greater survival benefit."
• "We plan to complete an End-of-Phase 2 meeting with the FDA in the first half of 2026 and finalize the protocol for a pivotal multinational Phase 3 trial, intended to deliver an innovative therapeutic option for patients diagnosed with this rapidly fatal disease."
• "We recognize that regulatory clarity on development pathways is essential for the on-going partnering efforts for our VCN-01 clinical programs."

Industry Context

Pancreatic ductal adenocarcinoma (PDAC) is a rapidly fatal disease, often diagnosed in late stages, with only 10% of cases resectable at presentation. There is a high unmet medical need for innovative therapeutic options. VCN-01, an oncolytic adenovirus, represents a novel approach designed to selectively replicate within tumor cells, degrade tumor stroma, and enhance the efficacy of co-administered chemotherapy and immunotherapy. The positive scientific advice from the EMA for a Phase 3 trial design is a significant step in a challenging oncology landscape, potentially positioning VCN-01 as a new treatment for a disease with limited effective options.

Comparison to Industry Standards

• The filing highlights that PDAC accounts for over 90% of pancreatic tumors and is often diagnosed at late, metastatic stages, making surgical resection impossible for most patients. This underscores the high unmet need, a common characteristic in oncology drug development where new therapies are urgently sought.
• VCN-01's mechanism of action as an oncolytic adenovirus that degrades tumor stroma and enhances chemotherapy access is a distinct approach compared to traditional chemotherapy or targeted therapies, aligning with the industry trend of developing multi-modal and immuno-oncology agents.
• The company's previous VIRAGE Phase 2b trial results, showing increased overall survival, progression-free survival, and duration of response, are positive indicators in a disease where survival improvements are often incremental. While no direct comparisons to specific competitor trial results are provided, these outcomes are generally considered favorable in the context of PDAC.
• The receipt of Orphan Drug and Fast Track designations in the USA and Europe for VCN-01 in metastatic PDAC, and Rare Pediatric Disease designation for retinoblastoma, indicates recognition by regulatory bodies of the significant medical need and potential benefit of the drug, a common industry benchmark for promising therapies in rare or severe diseases.

Stakeholder Impact

• Shareholders: Positive impact due to significant regulatory clarity and validation for a key pipeline asset, potentially de-risking future development and increasing the likelihood of successful commercialization and partnerships.
• Patients (Metastatic PDAC): Potential for a new, innovative therapeutic option for a rapidly fatal disease with high unmet need, offering improved survival outcomes.
• Employees: Positive impact from clear progress in clinical development and potential for future growth and success.
• Partners/Potential Partners: Increased attractiveness of VCN-01 programs due to regulatory clarity, which is essential for ongoing partnering efforts.
• Regulatory Authorities: The EMA's advice demonstrates a collaborative approach to advancing promising therapies for serious conditions.

Next Steps

• Schedule an End-of-Phase 2 meeting with the FDA in H1 2026 to finalize the protocol for a pivotal multinational Phase 3 clinical trial for VCN-01 in metastatic PDAC.
• Interact with EMA and FDA in 2026 to seek advice on a potential Phase 2/3 trial for VCN-01 in retinoblastoma.
• Pursue partnerships to support VCN-01 manufacturing scale-up and conduct of the proposed pivotal clinical trial(s).

Key Dates

Recommendation

The positive scientific advice from the EMA for the VCN-01 Phase 3 trial in metastatic pancreatic cancer is a significant de-risking event for Theriva Biologics. EMA's agreement on the trial design, including key endpoints and dosing, validates the company's development strategy and prior Phase 2b results. This regulatory clarity, coupled with existing Fast Track and Orphan Drug designations, enhances the probability of success for a drug targeting a high-unmet-need indication. The company's cash runway into Q1 2027 provides sufficient time to advance regulatory activities and pursue partnerships, which are crucial for funding the pivotal trial. This news provides a strong catalyst for potential upside, making it an attractive opportunity for investors.

Keywords

Theriva Biologics, TOVX, VCN-01, Pancreatic Cancer, Metastatic Pancreatic Ductal Adenocarcinoma, PDAC, Oncolytic Adenovirus, Phase 3 Clinical Trial, EMA, European Medicines Agency, CHMP, Orphan Drug, Fast Track, Oncology, Biotechnology, Clinical Stage, Drug Development